Clinical trial
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
NCT02531113 · Celgene, Industry · Completed
Key facts
| NCT number | NCT02531113 |
|---|---|
| Title | Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease |
| Official title | A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | RPC1063 |
| Enrollment | 69 |
| Start date | Oct 9, 2015 |
| Primary completion | Sep 12, 2019 |
| Completion | Nov 28, 2019 |
| First posted | Aug 24, 2015 |
| Last update posted | Jan 22, 2021 |
| Countries | Canada, Hungary, Poland, Ukraine, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: